title: Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.
abstract: The major dilemma of cancer chemotherapy has always been a double-edged sword, producing resistance in tumor cells and life-threatening destruction of nontumorigenic tissue. Glioblastoma is the most common form of primary brain tumor, with median survival at 14 months after surgery, radiation and temozolomide (monofunctional alkylator) therapy. Treatment failure is most often due to temozolomide-resistant tumor growth. The underlying basis for development of tumor cell resistance to temozolomide instead of death is not understood. Our current results demonstrate that both cervical carcinoma (HeLa MR) and glioblastoma (U251) tumor cells exposed to an equivalent chemotherapeutic concentration of a monofunctional alkylator undergo multiple cell cycles, maintenance of metabolic activity, and a prolonged time to death that involves accumulation of Apoptosis Inducing Factor (AIF) within the nucleus. A minority of the tumor cell population undergoes senescence, with minimal caspase cleavage. Surviving tumor cells are comprised of a very small subpopulation of individual cells that eventually resume proliferation, out of which resistant cells emerge. In contrast, normal human cells (MCF12A) exposed to a monofunctional alkylator undergo an immediate decrease in metabolic activity and subsequent senescence. A minority of the normal cell population undergoes cell death by the caspase cleavage pathway. All cytotoxic events occur within the first cell cycle in nontumorigenic cells. In summation, we have demonstrated that two different highly malignant tumor cell lines slowly undergo very altered cellular and temporal responses to chemotherapeutic monofunctional alkylation, as compared to rapid responses of normal cells. In the clinic, this produces resistance and growth of tumor cells, cytotoxicity of normal cells, and death of the patient.
authors.affiliation: Amgen, Seattle, Washington, United States of America.
authors.forename: Maithili
authors.initials: M
authors.lastname: Gupte
authors.forename: Andrew N
authors.initials: AN
authors.lastname: Tuck
authors.forename: Vishal P
authors.initials: VP
authors.lastname: Sharma
authors.forename: Kandace J
authors.initials: KJ
authors.lastname: Williams
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D051033:Apoptosis Inducing Factor / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D019070:Cell Lineage; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D024202:Electrophoretic Mobility Shift Assay; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology*; D000077204:Temozolomide
chemical_list: C494829:AIFM1 protein, human; D018906:Antineoplastic Agents, Alkylating; D051033:Apoptosis Inducing Factor; D009363:Neoplasm Proteins; D008769:Methylnitronitrosoguanidine; D003606:Dacarbazine; D000077204:Temozolomide
references.citation: J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):753-60
references.pmid: 22396442
references.citation: Genes Dev. 2004 Jun 1;18(11):1331-44
references.pmid: 15175264
references.citation: Cancer Res. 1995 Sep 1;55(17):3721-5
references.pmid: 7641183
references.citation: J Biol Chem. 2006 Dec 15;281(50):38244-56
references.pmid: 17050527
references.citation: Nat Rev Cancer. 2004 Apr;4(4):296-307
references.pmid: 15057289
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5107-13
references.pmid: 20823149
references.citation: J Cell Biol. 2004 Jun 21;165(6):835-42
references.pmid: 15210730
references.citation: Cancer Res. 1997 Sep 15;57(18):3949-55
references.pmid: 9307278
references.citation: Circ Res. 2012 Jun 22;111(1):97-109
references.pmid: 22723221
references.citation: Clin Cancer Res. 1997 Dec;3(12 Pt 1):2393-8
references.pmid: 9815639
references.citation: Oncogene. 2013 Mar 21;32(12):1539-48
references.pmid: 22614016
references.citation: Clin Cancer Res. 2000 Jul;6(7):2585-97
references.pmid: 10914698
references.citation: Nat Rev Cancer. 2010 Apr;10(4):293-301
references.pmid: 20200537
references.citation: Reprod Sci. 2007 Jan;14(1):20-8
references.pmid: 17636212
references.citation: Mutat Res. 2000 Apr;462(2-3):71-82
references.pmid: 10767619
references.citation: Curr Opin Genet Dev. 2011 Feb;21(1):107-12
references.pmid: 21093253
references.citation: Physiol Rev. 2007 Jan;87(1):99-163
references.pmid: 17237344
references.citation: Int J Biochem Mol Biol. 2012;3(1):1-27
references.pmid: 22509477
references.citation: Nat Cell Biol. 2012 Mar 18;14(4):355-65
references.pmid: 22426077
references.citation: Clin Cancer Res. 2013 Mar 1;19(5):977-84
references.pmid: 23269547
references.citation: Annu Rev Pathol. 2010;5:33-50
references.pmid: 19737106
references.citation: Antioxid Redox Signal. 2011 Jun 15;14(12):2545-79
references.pmid: 20868295
references.citation: Mol Cancer Res. 2013 Jan;11(1):13-8
references.pmid: 23193155
references.citation: Cancer Res. 2004 Jan 15;64(2):517-22
references.pmid: 14744764
references.citation: Carcinogenesis. 2003 Aug;24(8):1337-45
references.pmid: 12807730
references.citation: Cancer Treat Rev. 1997 Jan;23(1):35-61
references.pmid: 9189180
references.citation: Sci Signal. 2011 Apr 05;4(167):ra20
references.pmid: 21467298
references.citation: J Biol Chem. 2011 Mar 25;286(12):10411-8
references.pmid: 21285353
references.citation: Cancer Res. 2009 Aug 1;69(15):6307-14
references.pmid: 19638578
references.citation: Mol Cancer Ther. 2009 Feb;8(2):407-14
references.pmid: 19174557
references.citation: J Med Invest. 2004 Aug;51(3-4):146-53
references.pmid: 15460900
references.citation: Nature. 2005 Aug 4;436(7051):725-30
references.pmid: 16079851
references.citation: Cancer Cell. 2004 Aug;6(2):139-50
references.pmid: 15324697
references.citation: J Biol Chem. 2006 Aug 11;281(32):22674-83
references.pmid: 16772289
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15387-92
references.pmid: 14657349
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18314-9
references.pmid: 17116881
references.citation: Trends Biochem Sci. 2010 May;35(5):278-87
references.pmid: 20138767
references.citation: DNA Repair (Amst). 2008 Jun 1;7(6):951-69
references.pmid: 18468964
references.citation: Cancer Discov. 2013 Jan;3(1):20-3
references.pmid: 23319766
references.citation: Dev Cell. 2010 May 18;18(5):802-13
references.pmid: 20493813
references.citation: Carcinogenesis. 1997 Jan;18(1):1-8
references.pmid: 9054582
references.citation: Carcinogenesis. 2003 Apr;24(4):625-35
references.pmid: 12727789
references.citation: Int J Environ Res Public Health. 2012 Aug;9(8):2636-57
references.pmid: 23066388
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4622-9
references.pmid: 19584161
references.citation: J Biol Chem. 2010 Feb 19;285(8):5974-82
references.pmid: 20029092
references.citation: J Neurochem. 2012 Jul;122(2):444-55
references.pmid: 22564186
references.citation: Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
references.pmid: 7568133
references.citation: EMBO J. 2005 Apr 6;24(7):1375-86
references.pmid: 15775970
references.citation: Mol Cell. 2006 May 19;22(4):501-10
references.pmid: 16713580
references.citation: Nat Rev Cancer. 2009 Sep;9(9):665-74
references.pmid: 19693095
references.citation: Cancer Res. 2006 Apr 15;66(8):3987-91
references.pmid: 16618716
references.citation: Mol Cancer. 2011 Jun 06;10:69
references.pmid: 21639944
references.citation: Cancer Res. 1994 Feb 1;54(3):649-52
references.pmid: 8306326
references.citation: Neuro Oncol. 2013 Mar;15(3):370-81
references.pmid: 23328811
references.citation: Exp Cell Res. 2007 Jan 15;313(2):292-304
references.pmid: 17157834
references.citation: J Biol Chem. 2011 Aug 26;286(34):29531-9
references.pmid: 21725088
references.citation: Mol Cancer Ther. 2006 Sep;5(9):2182-92
references.pmid: 16985051
references.citation: Clin Cancer Res. 2007 Apr 1;13(7):2038-45
references.pmid: 17404084
references.citation: Genes Dev. 2010 Nov 15;24(22):2463-79
references.pmid: 21078816
references.citation: Anticancer Res. 2009 Oct;29(10):3759-68
references.pmid: 19846906
references.citation: Int J Oncol. 2006 Oct;29(4):785-97
references.pmid: 16964376
references.citation: Pharmacol Ther. 2010 Oct;128(1):1-36
references.pmid: 20546782
references.citation: Oncogene. 2013 Jan 10;32(2):171-9
references.pmid: 22410783
references.citation: J Biol Chem. 2009 Aug 7;284(32):21536-44
references.pmid: 19515846
references.citation: Clin Cancer Res. 2010 Jan 15;16(2):376-83
references.pmid: 20068082